Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R. Mato, José‐Ángel Hernández‐Rivas, Jennifer R. Brown et al.|Blood|2020Cited by 318
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, William G. Wierda, Barbara Eichhorst et al.|Journal of Clinical Oncology|2018Cited by 313
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R. Mato, Wojciech Jurczak, Jennifer A. Woyach et al.|New England Journal of Medicine|2023Cited by 213
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, Peter Hillmen, David A. Cairns et al.|New England Journal of Medicine|2023Cited by 155
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R. Mato, Colleen Dorsey, Lindsey E. Roeker et al.|Clinical Cancer Research|2020Cited by 115